MA33003B1 - Solutions pediatriques comprenant un betabloquant - Google Patents

Solutions pediatriques comprenant un betabloquant

Info

Publication number
MA33003B1
MA33003B1 MA34064A MA34064A MA33003B1 MA 33003 B1 MA33003 B1 MA 33003B1 MA 34064 A MA34064 A MA 34064A MA 34064 A MA34064 A MA 34064A MA 33003 B1 MA33003 B1 MA 33003B1
Authority
MA
Morocco
Prior art keywords
blockers
treatment
solution
containing beta
children containing
Prior art date
Application number
MA34064A
Other languages
Arabic (ar)
English (en)
Inventor
Christine Chaumont
Jean-François Cordoliani
Elie Leverd
Valérie Muguet
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40940328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of MA33003B1 publication Critical patent/MA33003B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Seasonings (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur des solutions non alcoolisées aqueuses comprenant un bétabloquant, un édulcorant de type non sucre et étant sensiblement exemptes d'un agent conservateur aromatique. Les solutions de la présente invention sont particulièrement adaptées pour une utilisation pédiatrique.
MA34064A 2009-04-21 2010-04-12 Solutions pediatriques comprenant un betabloquant MA33003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09290298A EP2246044A1 (fr) 2009-04-21 2009-04-21 Solutions pédiatriques de bêta-bloquants
PCT/IB2010/051573 WO2010122442A1 (fr) 2009-04-21 2010-04-12 Solutions pédiatriques comprenant un bétabloquant

Publications (1)

Publication Number Publication Date
MA33003B1 true MA33003B1 (fr) 2012-01-02

Family

ID=40940328

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34064A MA33003B1 (fr) 2009-04-21 2010-04-12 Solutions pediatriques comprenant un betabloquant

Country Status (32)

Country Link
US (2) US20120035270A1 (fr)
EP (4) EP2246044A1 (fr)
JP (1) JP5695029B2 (fr)
KR (1) KR101713866B1 (fr)
CN (1) CN102405041A (fr)
AR (2) AR076338A1 (fr)
AU (1) AU2010240551B2 (fr)
BR (1) BRPI1015447B1 (fr)
CA (1) CA2755175C (fr)
CL (1) CL2011002634A1 (fr)
CO (1) CO6410278A2 (fr)
CY (2) CY1119390T1 (fr)
DK (2) DK2421504T4 (fr)
ES (2) ES2685178T5 (fr)
GE (1) GEP20146087B (fr)
HR (2) HRP20170610T4 (fr)
HU (2) HUE039937T2 (fr)
IL (1) IL214674A (fr)
LT (2) LT2421504T (fr)
MA (1) MA33003B1 (fr)
MX (1) MX337463B (fr)
NZ (1) NZ594592A (fr)
PL (2) PL2497461T5 (fr)
PT (2) PT2497461T (fr)
RS (2) RS57668B2 (fr)
RU (1) RU2011139233A (fr)
SG (1) SG172960A1 (fr)
SI (2) SI2497461T2 (fr)
TN (1) TN2011000350A1 (fr)
TW (1) TWI429459B (fr)
UA (1) UA107570C2 (fr)
WO (1) WO2010122442A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246044A1 (fr) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants
SI3287123T1 (sl) 2011-03-04 2020-07-31 Gruenenthal Gmbh Vodna farmacevtska formulacija tapentadola za peroralno uporabo
JP2019142972A (ja) * 2011-03-04 2019-08-29 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング タペンタドールの非経口的投与
SI2680833T1 (sl) * 2011-03-04 2016-06-30 Gruenenthal Gmbh Parenteralno dajanje tapentadola
US9724297B2 (en) * 2014-04-01 2017-08-08 Arbor Pharmaceuticals, Inc. Sotalol compositions and uses of the same
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
BR112019005439A2 (pt) 2016-09-23 2019-06-18 Gruenenthal Gmbh formulação estável para administração parenteral de tapentadol
CN108261411B (zh) * 2016-12-30 2021-04-30 武汉科福新药有限责任公司 用于婴幼儿血管瘤治疗的口腔膜剂及其制备方法
CN107320467A (zh) * 2017-07-21 2017-11-07 江苏云阳集团药业有限公司 一种盐酸普萘洛尔药用组合物及其制备方法
CN108299279B (zh) * 2018-02-09 2021-03-23 北京梅尔森医药技术开发有限公司 取代芳基胺醇化合物及其制备方法和用途
US11547123B2 (en) * 2019-08-16 2023-01-10 The Folger Coffee Company Methods for reducing negative flavor attributes in coffee and compositions therefrom
EP4223283A1 (fr) 2020-09-30 2023-08-09 Nissan Chemical Corporation Complexe hydrosoluble contenant un beta-bloquant et de la lécithine
CN118021718B (zh) * 2024-04-12 2024-07-02 成都瑞尔医药科技有限公司 一种盐酸普罗帕酮注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600708A (en) 1985-07-19 1986-07-15 American Home Products Corporation Propranolol hydrochloride liquid formulations
HU209251B (en) * 1992-03-13 1994-04-28 Synepos Ag Process for producing stable, peroral solution drug forms with controlled release of active ingredient and comprising beta-blocking pharmacons
EP0732064B1 (fr) 1995-03-15 2001-06-06 Kao Corporation Utilisation d'un agent pour réduire l'amertume
JPH1025253A (ja) * 1996-07-12 1998-01-27 Kao Corp 苦味低減化剤及び苦味低減化法
JPH11349492A (ja) * 1998-06-03 1999-12-21 Yamanouchi Pharmaceut Co Ltd 苦味を低減した経口用医薬組成物および苦味低減化方法
JP2001342151A (ja) * 2000-03-31 2001-12-11 Eisai Co Ltd 甘味を有する薬剤組成物
NZ529173A (en) * 2001-05-25 2005-07-29 Warner Lambert Co Stable liquid pharmaceutical composition comprising a GABA analog i.e. gabapentin or pregabalin, and a polyhydric alcohol e.g. glycerol, xylitol, sorbitol, mannitol
EP1543831A1 (fr) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Composition de pregabaline
WO2006093493A1 (fr) * 2005-02-25 2006-09-08 Biomarin Pharmaceutical Inc. Composition pharmaceutique liquide aqueuse stable a temperature ambiante
EP1888030A1 (fr) * 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Formulation pédiatrique de topiramate
DE102006020604A1 (de) * 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2050441A1 (fr) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes
SI2268282T1 (sl) * 2008-04-25 2015-01-30 Apotex Technologies Inc. Tekoča farmacevtska oblika deferiprona s prijetnim okusom
EP2246044A1 (fr) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Solutions pédiatriques de bêta-bloquants

Also Published As

Publication number Publication date
AR117621A2 (es) 2021-08-18
BRPI1015447A8 (pt) 2017-10-03
MX337463B (es) 2016-03-07
RS55862B2 (sr) 2022-12-30
HRP20181408T4 (hr) 2022-03-04
HUE039937T2 (hu) 2019-02-28
RS57668B2 (sr) 2022-03-31
ES2623936T3 (es) 2017-07-12
PL2421504T5 (pl) 2023-01-02
RU2011139233A (ru) 2013-05-27
EP2497461B1 (fr) 2018-06-20
SI2421504T1 (sl) 2017-06-30
SI2497461T1 (sl) 2018-10-30
UA107570C2 (xx) 2015-01-26
KR101713866B1 (ko) 2017-03-09
CY1119390T1 (el) 2018-02-14
LT2497461T (lt) 2018-10-10
PT2421504T (pt) 2017-06-16
CY1120667T1 (el) 2019-12-11
GEP20146087B (en) 2014-05-13
US20150087719A1 (en) 2015-03-26
EP2497461B2 (fr) 2021-12-15
HRP20170610T1 (hr) 2017-07-28
CA2755175C (fr) 2018-01-02
CO6410278A2 (es) 2012-03-30
CA2755175A1 (fr) 2010-10-28
SG172960A1 (en) 2011-08-29
JP2012524773A (ja) 2012-10-18
PL2497461T3 (pl) 2018-12-31
HRP20170610T4 (hr) 2022-12-09
TW201039862A (en) 2010-11-16
US20120035270A1 (en) 2012-02-09
RS57668B1 (sr) 2018-11-30
IL214674A0 (en) 2011-09-27
ES2685178T3 (es) 2018-10-05
DK2421504T4 (da) 2022-11-14
BRPI1015447A2 (pt) 2016-04-19
WO2010122442A1 (fr) 2010-10-28
EP2421504A1 (fr) 2012-02-29
TN2011000350A1 (en) 2013-03-27
PL2497461T5 (pl) 2022-06-27
NZ594592A (en) 2013-11-29
PT2497461T (pt) 2018-10-23
KR20120015305A (ko) 2012-02-21
HUE034581T2 (en) 2018-02-28
BRPI1015447B1 (pt) 2020-01-28
AU2010240551B2 (en) 2015-07-16
SI2497461T2 (sl) 2022-04-29
RS55862B1 (sr) 2017-08-31
CL2011002634A1 (es) 2012-06-08
HRP20181408T1 (hr) 2018-11-02
LT2421504T (lt) 2017-06-12
EP2421504B1 (fr) 2017-03-08
DK2421504T3 (en) 2017-05-01
AR076338A1 (es) 2011-06-01
DK2497461T3 (en) 2018-09-03
IL214674A (en) 2017-01-31
EP2421504B2 (fr) 2022-08-10
EP3384899A1 (fr) 2018-10-10
ES2685178T5 (es) 2022-04-13
PL2421504T3 (pl) 2017-08-31
TWI429459B (zh) 2014-03-11
EP2497461A2 (fr) 2012-09-12
EP2246044A1 (fr) 2010-11-03
ES2623936T5 (es) 2022-11-28
MX2011010766A (es) 2011-10-21
CN102405041A (zh) 2012-04-04
JP5695029B2 (ja) 2015-04-01
EP2497461A3 (fr) 2014-01-01
DK2497461T4 (da) 2022-02-14
AU2010240551A1 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
MA33003B1 (fr) Solutions pediatriques comprenant un betabloquant
PL1904029T5 (pl) Podawana doustnie, nie dająca się wypluć folia, ulegająca szybkiemu rozkładowi, zawierająca olanzapinę
WO2008137785A3 (fr) Système de traitement de l'eau, et procédés de nettoyage en aval
WO2009155932A3 (fr) Modulation du système récepteur trpv/récepteur du domaine op vps1 pour le traitement de la douleur
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2007096885A3 (fr) Formulations contenant un biocide non oxydant et une source d'halogene actif et son utilisation pour le traitement de l'eau
WO2010085100A2 (fr) Nouveau domaine transmembranaire cellulaire et système de transduction intracellulaire contenant ce domaine
NO20081487L (no) Helsefremmende drikk
BR9906621A (pt) Dicarboalcóxi dioxolanos
WO2009007411A3 (fr) Inhibition de la formation des ages
MA30133B1 (fr) Concentre emballe permettant de preparer un bouillon, une soupe, une sauce, un jus ou a utiliser comme assaisonnement, le concentre comprenant les gommes de xanthane et de cassia
WO2007124476A3 (fr) Solutions aqueuses ophtalmiques et apparentées contenant des agents antifongiques, leurs utilisations et leurs procédés de préparation
BRPI0811881A8 (pt) Condimento, alimento ou bebida, composição, e método para melhorar o sabor de um sal de potássio
WO2009068275A3 (fr) DÉRIVÉS D'ACIDES α-AMINÉS POUR L'AMÉLIORATION DE LA SOLUBILITÉ
FR2904756B1 (fr) Dispositif de maintien des seins pour application medicale.
BR112013030904A2 (pt) Composição de peptídeos, composição de aroma, e, alimento ou bebida
FR2937421B1 (fr) Determination de la concentration en sel d'une solution aqueuse.
HK1149508A1 (en) Melanogenesis inhibitor and skin-whitening agent
WO2009080349A3 (fr) Gestion de l'eau de nettoyage en place pour l'embouteillage et le brassage
WO2007017259A3 (fr) Utilisation de trifluoromethylcetones specifiques pour prevenir et traiter une pancreatite
Schoenstein Determination of Bromate by different IC and IC/MS methods
EA201390882A1 (ru) Напитки на основе чая
안선희 Deep Skin
Chernykh et al. KG-MEIS complex for study of surfaces and nanostructures; Kompleks KG-MEIS dlya issledovaniya poverkhnosti i nanoslojnykh struktur
Герасимов et al. System of multidirectional financing of innovation projects